Summary:
A Randomized, Double Blind, Placebo Controlled, Single Ascending Dose Study with Lurasidone Injectable Suspension to Evaluate Safety, Tolerability, and Pharmacokinetics in Subjects with Schizophrenia
Qualified Participants Must:
1. Subject is male or female 18 to 65 years of age
2. Subject has a diagnosis of schizophrenia
Qualified Participants May Receive:
Compensation for time and travel